ArticleNeuro-oncology2016
Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function.
Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Effects of theInternational journal of molecular sciences · 2021Pooled it
- A brain-penetrant chimeric protein combines direct glioma targeting with myeloid cell-mediated immune reprogramming.Journal of translational medicine · 2026Article
- Potential of ex vivo organotypic slice cultures in neuro-oncology.Neuro-oncology · 2025Review
- The Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges.Microorganisms · 2024Review
- Some Examples of Bacterial Toxins as Tools.Toxins · 2024Review
- Molecular changes underlying decay of sensory responses and enhanced seizure propensity in peritumoral neurons.Neuro-oncology · 2023Article
- Biomimetic three-dimensional glioma model printedInternational journal of bioprinting · 2023Article
- Bacteria associated with glioma: a next wave in cancer treatment.Frontiers in cellular and infection microbiology · 2023Review
- LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression.BMC cancer · 2022Article
- Article
- Crystal structure of bacterial cytotoxic necrotizing factor CNFThe EMBO journal · 2021Article
- Voluntary Physical Exercise Reduces Motor Dysfunction and Hampers Tumor Cell Proliferation in a Mouse Model of Glioma.International journal of environmental research and public health · 2020Article
- Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies.Toxins · 2020Article
- Article
- Bacterial Toxins and Targeted Brain Therapy: New Insights from Cytotoxic Necrotizing Factor 1 (CNF1).International journal of molecular sciences · 2018Review
- Specific role of RhoC in tumor invasion and metastasis.Oncotarget · 2017Article
- Remodeling the blood-brain barrier microenvironment by natural products for brain tumor therapy.Acta pharmaceutica Sinica. B · 2017Review
- Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages.Oncotarget · 2017Article
- Ultra-High Mass Resolution MALDI Imaging Mass Spectrometry of Proteins and Metabolites in a Mouse Model of Glioblastoma.Scientific reports · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastomas are the most aggressive type of brain tumor. A successful treatment should aim at halting tumor growth and protecting neuronal cells to prevent functional deficits and cognitive deterioration. Here, we exploited a Rho GTPase-activating bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1), to interfere with glioma cell growth in vitro and vivo. We also investigated whether this toxin spares neuron structure and function in peritumoral areas.
methodsWe performed a microarray transcriptomic and in-depth proteomic analysis to characterize the molecular changes triggered by CNF1 in glioma cells. We also examined tumor cell senescence and growth in vehicle- and CNF1-treated glioma-bearing mice. Electrophysiological and morphological techniques were used to investigate neuronal alterations in peritumoral cortical areas.
resultsAdministration of CNF1 triggered molecular and morphological hallmarks of senescence in mouse and human glioma cells in vitro. CNF1 treatment in vivo induced glioma cell senescence and potently reduced tumor volumes. In peritumoral areas of glioma-bearing mice, neurons showed a shrunken dendritic arbor and severe functional alterations such as increased spontaneous activity and reduced visual responsiveness. CNF1 treatment enhanced dendritic length and improved several physiological properties of pyramidal neurons, demonstrating functional preservation of the cortical network.
conclusionsOur findings demonstrate that CNF1 reduces glioma volume while at the same time maintaining the physiological and structural properties of peritumoral neurons. These data indicate a promising strategy for the development of more effective antiglioma therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.